TriangleNCT04068896 · STUDY IN CONTEXT
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Draft scope assessment: unclear. Attached because the study's own record describes metastatic disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
Read the full study record and all posted results →
Linked outcomes
Reported safety
Quality of life and patient-reported measures
No linked quality-of-life measure is recorded for this setting and study.
Full draft applicability and source-link record
- trial
- release id
- clinical-indications-draft-1
- disease state id
- ds-pancreatic-cancer-metastatic-aecf3979
- nct id
- NCT04068896
- trial label
- Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
- applicability
- unclear
- applicability note
- Attached because the study's own record describes metastatic disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- provenance class
- registry-condition-search
- discovery note
- Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
- outcome Count
- 3
- harms Count
- 6
- qol Count
- 0
- outcomes
- release id
- clinical-indications-draft-1
- disease state id
- ds-pancreatic-cancer-metastatic-aecf3979
- nct id
- NCT04068896
- outcome key
- om-0000
- source section id
- NCT04068896-om-0000
- source outcome index
- 0
- endpoint
- To Determine the Safety and Tolerability of NGM120 in Subjects
- endpoint definition
- Number of Participants with NGM120/Placebo-Related Treatment Emergent Adverse Events
- time origin
- From enrollment to end of treatment up to 24 months
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Safety analysis set
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-pancreatic-cancer-metastatic-aecf3979
- nct id
- NCT04068896
- outcome key
- om-0001
- source section id
- NCT04068896-om-0001
- source outcome index
- 1
- endpoint
- To Determine the Safety and Tolerability of NGM120
- endpoint definition
- Discontinuation of investigational product due to toxicity
- time origin
- From enrollment to end of treatment up to 24 months
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Safety analysis set
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-pancreatic-cancer-metastatic-aecf3979
- nct id
- NCT04068896
- outcome key
- om-0002
- source section id
- NCT04068896-om-0002
- source outcome index
- 2
- endpoint
- To Determine the Safety and Tolerability of NGM120
- endpoint definition
- Local injection-site symptom assessment as evidenced by incidence of injection-site reactions
- time origin
- From enrollment to end of treatment up to 24 months
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Safety analysis set
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- arms
- release id
- clinical-indications-draft-1
- disease state id
- ds-pancreatic-cancer-metastatic-aecf3979
- nct id
- NCT04068896
- outcome key
- om-0000
- arm key
- OG000
- arm label
- Part 1 NGM120 30mg
- regimen
- NGM120 30mg Subcutaneous Injection
- analyzed count
- 10
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT04068896-om-0000#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-pancreatic-cancer-metastatic-aecf3979
- nct id
- NCT04068896
- outcome key
- om-0000
- arm key
- OG001
- arm label
- Part 1 NGM120 100mg
- regimen
- NGM120 100mg Subcutaneous Injection
- analyzed count
- 10
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT04068896-om-0000#groups/OG001
- release id
- clinical-indications-draft-1
- disease state id
- ds-pancreatic-cancer-metastatic-aecf3979
- nct id
- NCT04068896
- outcome key
- om-0000
- arm key
- OG002
- arm label
- Part 2 NGM120 30mg
- regimen
- NGM120 30mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).
- analyzed count
- 10
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT04068896-om-0000#groups/OG002
- release id
- clinical-indications-draft-1
- disease state id
- ds-pancreatic-cancer-metastatic-aecf3979
- nct id
- NCT04068896
- outcome key
- om-0000
- arm key
- OG003
- arm label
- Part 2 NGM120 100mg
- regimen
- NGM120 100mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).
- analyzed count
- 31
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT04068896-om-0000#groups/OG003
- release id
- clinical-indications-draft-1
- disease state id
- ds-pancreatic-cancer-metastatic-aecf3979
- nct id
- NCT04068896
- outcome key
- om-0000
- arm key
- OG004
- arm label
- Part 2 Placebo
- regimen
- Placebo Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).
- analyzed count
- 20
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT04068896-om-0000#groups/OG004
- release id
- clinical-indications-draft-1
- disease state id
- ds-pancreatic-cancer-metastatic-aecf3979
- nct id
- NCT04068896
- outcome key
- om-0000
- arm key
- OG005
- arm label
- Part 3 NGM120 100mg
- regimen
- NGM120 100mg Subcutaneous Injection
- analyzed count
- 6
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT04068896-om-0000#groups/OG005
- release id
- clinical-indications-draft-1
- disease state id
- ds-pancreatic-cancer-metastatic-aecf3979
- nct id
- NCT04068896
- outcome key
- om-0001
- arm key
- OG000
- arm label
- Part 1 NGM120 30mg
- regimen
- NGM120 30mg Subcutaneous Injection
- analyzed count
- 10
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT04068896-om-0001#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-pancreatic-cancer-metastatic-aecf3979
- nct id
- NCT04068896
- outcome key
- om-0001
- arm key
- OG001
- arm label
- Part 1 NGM120 100mg
- regimen
- NGM120 100mg Subcutaneous Injection
- analyzed count
- 10
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT04068896-om-0001#groups/OG001
- release id
- clinical-indications-draft-1
- disease state id
- ds-pancreatic-cancer-metastatic-aecf3979
- nct id
- NCT04068896
- outcome key
- om-0001
- arm key
- OG002
- arm label
- Part 2 NGM120 30mg
- regimen
- NGM120 30mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).
- analyzed count
- 10
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT04068896-om-0001#groups/OG002
- release id
- clinical-indications-draft-1
- disease state id
- ds-pancreatic-cancer-metastatic-aecf3979
- nct id
- NCT04068896
- outcome key
- om-0001
- arm key
- OG003
- arm label
- Part 2 NGM120 100mg
- regimen
- NGM120 100mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).
- analyzed count
- 31
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT04068896-om-0001#groups/OG003
- release id
- clinical-indications-draft-1
- disease state id
- ds-pancreatic-cancer-metastatic-aecf3979
- nct id
- NCT04068896
- outcome key
- om-0001
- arm key
- OG004
- arm label
- Part 2 Placebo
- regimen
- Placebo Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).
- analyzed count
- 20
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT04068896-om-0001#groups/OG004
- release id
- clinical-indications-draft-1
- disease state id
- ds-pancreatic-cancer-metastatic-aecf3979
- nct id
- NCT04068896
- outcome key
- om-0001
- arm key
- OG005
- arm label
- Part 3 NGM120 100mg
- regimen
- NGM120 100 mg Subcutaneous Injection
- analyzed count
- 6
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT04068896-om-0001#groups/OG005
- harms
- release id
- clinical-indications-draft-1
- disease state id
- ds-pancreatic-cancer-metastatic-aecf3979
- nct id
- NCT04068896
- harm key
- EG000
- source section id
- NCT04068896-ae
- event group key
- EG000
- event group label
- Part 1 NGM120 30mg
- serious affected
- 5
- serious at risk
- 10
- other affected
- 10
- other at risk
- 10
- frequency threshold
- 0
- collection period
- 3 years, 8 months.
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-pancreatic-cancer-metastatic-aecf3979
- nct id
- NCT04068896
- harm key
- EG001
- source section id
- NCT04068896-ae
- event group key
- EG001
- event group label
- Part 1 NGM120 100mg
- serious affected
- 3
- serious at risk
- 10
- other affected
- 10
- other at risk
- 10
- frequency threshold
- 0
- collection period
- 3 years, 8 months.
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-pancreatic-cancer-metastatic-aecf3979
- nct id
- NCT04068896
- harm key
- EG002
- source section id
- NCT04068896-ae
- event group key
- EG002
- event group label
- Part 2 NGM120 30mg
- serious affected
- 5
- serious at risk
- 10
- other affected
- 10
- other at risk
- 10
- frequency threshold
- 0
- collection period
- 3 years, 8 months.
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-pancreatic-cancer-metastatic-aecf3979
- nct id
- NCT04068896
- harm key
- EG003
- source section id
- NCT04068896-ae
- event group key
- EG003
- event group label
- Part 2 NGM120 100mg
- serious affected
- 26
- serious at risk
- 31
- other affected
- 31
- other at risk
- 31
- frequency threshold
- 0
- collection period
- 3 years, 8 months.
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-pancreatic-cancer-metastatic-aecf3979
- nct id
- NCT04068896
- harm key
- EG004
- source section id
- NCT04068896-ae
- event group key
- EG004
- event group label
- Part 2 Placebo
- serious affected
- 10
- serious at risk
- 20
- other affected
- 20
- other at risk
- 20
- frequency threshold
- 0
- collection period
- 3 years, 8 months.
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-pancreatic-cancer-metastatic-aecf3979
- nct id
- NCT04068896
- harm key
- EG005
- source section id
- NCT04068896-ae
- event group key
- EG005
- event group label
- Part 3 NGM120 100mg
- serious affected
- 1
- serious at risk
- 6
- other affected
- 6
- other at risk
- 6
- frequency threshold
- 0
- collection period
- 3 years, 8 months.
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- quality of life
- setting source links
Preserved source evidence · Not medical advice